▎ 摘　　要

NOVELTY - Conductive hydrogel consists essentially of or consists of: a polysterene sulfonate compound comprising poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), reduced graphene oxide polystyrene sulfonate (rGO:PSS) and rGO:PEDOT:PSS; and a conjugate of oligopeptide and polyethylene glycol (PEG) (I). USE - The conductive hydrogel is useful in biomedical applications comprising neuroprostheses, biosensors, nerve grafts, cell culture, cell storage, and drug delivery (claimed). No biological data given. ADVANTAGE - The conductive hydrogel: exhibits less crosslinking; is stable, and easy and cheap to produce; exhibit improved self-healing and molecular ordering, tuneability of rheological properties and electrical impedance, injectability and biocompatibility; mimics the extracellular matrix properly; and utilizes conductive polymer that is capable of passing electronic or ionic charges. DETAILED DESCRIPTION - Conductive hydrogel consists essentially of or consists of: a polysterene sulfonate compound comprising poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), reduced graphene oxide polystyrene sulfonate (rGO:PSS) and rGO:PEDOT:PSS; and a conjugate of oligopeptide and polyethylene glycol (PEG) of formula (I). B1 = lysine or arginine; X = alanine, glycine, serine, threonine, tyrosine, glutamic acid or aspartic acid; and n = 3-20. INDEPENDENT CLAIMS are also included for: (1) a process (P1) for preparing the conductive hydrogel, comprising: (a) preparing a conjugate (I), (b) mixing the conjugate of PEG and an oligopeptide of formula (I) with a polysterene sulfonate compound, (c) forming the conductive hydrogel matrix by gelation, and optional, when the hydrogel comprises cells or organoids, (d) seeding the cells or organoids onto the hydrogel matrix obtained by step (c), and (e) incubating the hydrogel matrix and the seeded cells or organoids to facilitate cell adhesion to the conductive hydrogel matrix; (2) a process (P2) for preparing a conductive hydrogel comprising cells or organoids, comprising: (a1) preparing a conjugate of PEG and a linker-oligopeptide (I), (b1) premixing cells or organoids with a polystyrene sulfonate compound in a culture medium, (c1) mixing the conjugate of PEG and an oligopeptide of (I) with the culture medium comprising the cells or organoids premixed with a polystyrene sulfonate compound, and (d1) forming the conductive hydrogel matrix by gelation to encapsulate the cells or organoids into the hydrogel matrix; and (3) a process (P3) for preparing a conductive hydrogel comprising a morphogen or an active ingredient, comprising the step (a1) as above per se, (b2) premixing an active ingredient or morphogen with a polystyrene sulfonate compound in solution, preferably in aqueous solution, (c2) mixing the conjugate of PEG and an oligopeptide of (I) of step (a1) with the solution of step (b2) comprising the premixed active ingredient or morphogen and a polystyrene sulfonate compound, and (d2) forming the conductive hydrogel matrix by gelation.